AstraZeneca uses genomics and proteomics software

AstraZeneca is using Cambridge Cell Network’s (CCnet) genomics and proteomics software ToxWiz to predict the effects of drugs used to treat liver disease.

The user-friendly approach provides a quick way to determine the relationships between side effects and specific proteins or pathways. The software allows researchers to search computational models of more than 500 biological pathways. Each pathway can then connect to a database of 800,000 abstracts.

Dr Scott Bayer, principal scientist and head of computational toxicology at AstraZeneca, said: ‘CCnet is listening in earnest to toxicologists, providing solutions to challenges we face and making appropriate software modifications as they are requested.’

Twitter icon
Google icon icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon
Analysis and opinion

Robert Roe looks at research from the University of Alaska that is using HPC to change the way we look at the movement of ice sheets


Robert Roe talks to cooling experts to find out what innovation lies ahead for HPC users

Analysis and opinion